Maplight Therapeutics (NASDAQ:MPLT) Announces Earnings Results, Misses Estimates By $35.32 EPS

Maplight Therapeutics (NASDAQ:MPLT) announced its quarterly earnings data on Thursday. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32), Zacks reports.

Maplight Therapeutics Stock Up 8.4%

MPLT stock opened at $18.34 on Friday. Maplight Therapeutics has a 1 year low of $12.24 and a 1 year high of $20.86.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MPLT. Leerink Partners assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “outperform” rating and a $30.00 price target on the stock. Stifel Nicolaus assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 target price on the stock. Leerink Partnrs upgraded Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Finally, Zacks Research raised Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Maplight Therapeutics currently has an average rating of “Buy” and an average price target of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.